Role reversal of MAVS in bacterial sepsis
MAVS 在细菌性脓毒症中的作用逆转
基本信息
- 批准号:10439602
- 负责人:
- 金额:$ 48.24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-08-15 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAntibodiesBacteremiaBacteriaBacterial InfectionsBacterial RNABlood Coagulation DisordersBlood coagulationCRISPR/Cas technologyCellsCessation of lifeClinical TrialsCoagulation ProcessComplicationConsensusCritical CareCytosolDataDevelopmentDiseaseEngineeringEquilibriumEventExtravasationFDA approvedFamilyFunctional disorderFutureGene DeletionGene ExpressionGenesHistonesHumanImmuneImmune responseImmunosuppressionInfectionInterleukin-12Interleukin-6Knockout MiceLifeMicrobeMitochondriaMolecularMolecular TargetMorbidity - disease rateMouse ProteinMultiple Organ FailureMusOrganOutcomeOuter Mitochondrial MembranePathway interactionsPatternPhagocytesPharmacologic SubstancePharmacologyPhosphorylationProteomeRNARNA HelicaseResearchResistanceRoleSepsisShapesSignal PathwaySignal TransductionSignaling ProteinTBK1 geneTRAF2 geneTestingTherapeutic InterventionTissuesUnited StatesVirusVirus Diseasesbasecytokinecytotoxiceffective therapyexperimental studyextracellularfungusimmunopathologyinnovationinsightinterestmacrophagemicrobialmonocytemortalitymouse modelneutrophilnovelnovel therapeutic interventionpathogenpathogenic microbepolymerizationpolymicrobial sepsisprogramsprotein activationprotein degradationsensorsepticspatiotemporaltissue injurytranscription factortranscriptometranscriptome sequencingtranslational study
项目摘要
Sepsis is a frequent and life-threatening complication of microbial infections. It is estimated that more than
750,000 annual cases of sepsis occur in the United States and mortality rates remain around 20-50% despite
recent advances of critical care support. In the current absence of FDA-approved pharmacologic compounds,
there remains an urgent need for a complete characterization of the underlying cellular and molecular
mechanisms of sepsis. The dysregulated host response is a prominent feature during the pathophysiology of
bacterial sepsis, but the delicate balance of its integrating molecular pathways appear not entirely clear.
Mitochondrial antiviral-signaling protein (MAVS) is an adaptor molecule in the outer mitochondrial membrane
and is highly expressed in professional phagocytes. MAVS is activated by the cytoplasmic RNA helicases, RIG-
I and MDA5, and confers protection against viral infections. Surprisingly, our preliminary findings suggest
deletion of MAVS or RIG-I/MDA5 in mice confers immense resistance to mortality and modulates phagocyte
transcriptomes, immunoproteasomes, extracellular traps, IL-6/IL-12 cytokines and blood coagulation during
polymicrobial bacterial sepsis. Bacterial RNAs are a viability-associated pathogen patterns (`vita-PAMPs')
sensed by the MAVS pathway in macrophages. Together, these findings suggest a detrimental role reversal of
MAVS during bacterial sepsis as opposed to protective MAVS pathway functions during infections with viruses.
To test our central hypothesis that MAVS signaling provides a lethal switch for obstructing favorable sepsis
outcomes, we will pursue 3 specific aims: (1) We will study the gene expression, activation mechanisms,
signaling events and functional roles of MAVS in professional phagocytes (macrophages, neutrophils) during
polymicrobial bacterial sepsis. For these studies, mice with total or conditional gene deletion of MAVS, or the
RIG-I/MDA5 sensors are available. MAVS-deficient human macrophages will be generated using CRISPR-Cas9.
(2) We will determine how MAVS-induced transcription factors promote gene expression of immunoproteasome
subunits, what the pleiotropic functions of the immunoproteasome are during bacterial sepsis, and how the
immunoproteasome shapes the proteomes and transcriptomes of macrophages. These studies will include using
triple-knockout mice for all three regulatory immunoproteasome subunits (PSMB8/9/10). (3) We will study how
the MAVS pathway amplifies the harmful molecular sequelae of bacterial sepsis focusing on phagocyte
extracellular traps (NETs/METs), IL-6/IL-12 cytokines, septic coagulopathy and immunosuppression; which all
contribute to tissue injury, organ dysfunction and sepsis lethality. In particular, we will consider a novel role of
the immunoproteasome in subcellular protein degradation for facilitating extracellular trap formation. In summary,
elucidating the previously unsuspected involvement of the MAVS pathway during bacterial infection will provide
novel and important information and may add critical insights for guiding future efforts to develop effective
therapies for sepsis.
脓毒症是微生物感染的常见且危及生命的并发症。估计超过
美国每年发生 750,000 例败血症病例,尽管死亡率仍维持在 20-50% 左右
重症监护支持的最新进展。在目前尚无 FDA 批准的药理化合物的情况下,
仍然迫切需要对潜在的细胞和分子进行完整的表征
败血症的机制。宿主反应失调是病理生理学过程中的一个突出特征
细菌性败血症,但其整合分子途径的微妙平衡似乎并不完全清楚。
线粒体抗病毒信号蛋白 (MAVS) 是线粒体外膜中的接头分子
并且在专业吞噬细胞中高度表达。 MAVS 由细胞质 RNA 解旋酶 RIG- 激活
I 和 MDA5,并提供针对病毒感染的保护。令人惊讶的是,我们的初步研究结果表明
小鼠中 MAVS 或 RIG-I/MDA5 的缺失赋予了对死亡的巨大抵抗力并调节吞噬细胞
转录组、免疫蛋白酶体、细胞外陷阱、IL-6/IL-12 细胞因子和凝血过程
多种微生物细菌性败血症。细菌 RNA 是一种与活力相关的病原体模式(“vita-PAMP”)
由巨噬细胞中的 MAVS 通路感知。总之,这些发现表明了有害的角色逆转
细菌败血症期间的 MAVS 与病毒感染期间的保护性 MAVS 通路功能相反。
检验我们的中心假设,即 MAVS 信号传导提供了阻碍有利脓毒症的致命开关
成果,我们将追求 3 个具体目标:(1)我们将研究基因表达、激活机制,
MAVS 在专业吞噬细胞(巨噬细胞、中性粒细胞)中的信号事件和功能作用
多种微生物细菌性败血症。在这些研究中,MAVS 基因完全或有条件缺失的小鼠,或
提供 RIG-I/MDA5 传感器。 MAVS 缺陷的人类巨噬细胞将使用 CRISPR-Cas9 生成。
(2)我们将确定MAVS诱导的转录因子如何促进免疫蛋白酶体的基因表达
亚基,免疫蛋白酶体在细菌性脓毒症期间的多效性功能是什么,以及如何
免疫蛋白酶体塑造巨噬细胞的蛋白质组和转录组。这些研究将包括使用
所有三个调节性免疫蛋白酶体亚基的三重敲除小鼠(PSMB8/9/10)。 (3)我们将研究如何
MAVS 通路放大了针对吞噬细胞的细菌性败血症的有害分子后遗症
细胞外陷阱 (NETs/METs)、IL-6/IL-12 细胞因子、脓毒性凝血病和免疫抑制;其中所有
导致组织损伤、器官功能障碍和败血症致死。特别是,我们将考虑一个新颖的角色
亚细胞蛋白质降解中的免疫蛋白酶体促进细胞外陷阱的形成。总之,
阐明以前未曾怀疑的 MAVS 通路在细菌感染过程中的参与将提供
新颖且重要的信息,可能会增加重要的见解,以指导未来开发有效的工作
脓毒症的治疗方法。
项目成果
期刊论文数量(9)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Gut Microbiota Restricts NETosis in Acute Mesenteric Ischemia-Reperfusion Injury.
肠道微生物群限制急性肠系膜缺血再灌注损伤中的 NETosis。
- DOI:
- 发表时间:2020
- 期刊:
- 影响因子:0
- 作者:Ascher, Stefanie;Wilms, Eivor;Pontarollo, Giulia;Formes, Henning;Bayer, Franziska;Müller, Maria;Malinarich, Frano;Grill, Alexandra;Bosmann, Markus;Saffarzadeh, Mona;Brandão, Inês;Groß, Kathrin;Kiouptsi, Klytaimnistra;Kittner, Jens M;Lackner
- 通讯作者:Lackner
Neutrophil extracellular traps impair fungal clearance in a mouse model of invasive pulmonary aspergillosis.
中性粒细胞胞外陷阱损害侵袭性肺曲霉病小鼠模型中的真菌清除。
- DOI:
- 发表时间:2020
- 期刊:
- 影响因子:2.8
- 作者:Alflen, Astrid;Aranda Lopez, Pamela;Hartmann, Ann;Maxeiner, Joachim;Bosmann, Markus;Sharma, Arjun;Platten, Johannes;Ries, Frederic;Beckert, Hendrik;Ruf, Wolfram;Radsak, Markus P
- 通讯作者:Radsak, Markus P
STAT1 Isoforms Differentially Regulate NK Cell Maturation and Anti-tumor Activity.
STAT1 同种型差异调节 NK 细胞成熟和抗肿瘤活性。
- DOI:
- 发表时间:2020
- 期刊:
- 影响因子:0
- 作者:Meissl, Katrin;Simonović, Natalija;Amenitsch, Lena;Witalisz;Klein, Klara;Lassnig, Caroline;Puga, Ana;Vogl, Claus;Poelzl, Andrea;Bosmann, Markus;Dohnal, Alexander;Sexl, Veronika;Müller, Mathias;Strobl, Birgit
- 通讯作者:Strobl, Birgit
Activated Endothelial TGFβ1 Signaling Promotes Venous Thrombus Nonresolution in Mice Via Endothelin-1: Potential Role for Chronic Thromboembolic Pulmonary Hypertension.
激活的内皮TGFβ1 信号传导通过内皮素1 促进小鼠静脉血栓不消退:慢性血栓栓塞性肺动脉高压的潜在作用。
- DOI:
- 发表时间:2020
- 期刊:
- 影响因子:20.1
- 作者:Bochenek, Magdalena L;Leidinger, Christiane;Rosinus, Nico S;Gogiraju, Rajinikanth;Guth, Stefan;Hobohm, Lukas;Jurk, Kerstin;Mayer, Eckhard;Münzel, Thomas;Lankeit, Mareike;Bosmann, Markus;Konstantinides, Stavros;Schäfer, Katrin
- 通讯作者:Schäfer, Katrin
Response by Ascher et al to Letter Regarding Article, "Gut Microbiota Restricts NETosis in Acute Mesenteric Ischemia-Reperfusion Injury".
Ascher 等人对有关文章“肠道微生物群限制急性肠系膜缺血再灌注损伤中的 NETosis”的信件的回应。
- DOI:
- 发表时间:2021
- 期刊:
- 影响因子:0
- 作者:Ascher, Stefanie;Wilms, Eivor;Pontarollo, Giulia;Kiouptsi, Klytaimnistra;Malinarich, Frano;Kittner, Jens M;Bosmann, Markus;Jurk, Kerstin;Reinhardt, Christoph
- 通讯作者:Reinhardt, Christoph
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Markus Bosmann其他文献
Markus Bosmann的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Markus Bosmann', 18)}}的其他基金
Interleukin-27 in host response to Legionella infection
Interleukin-27 在宿主对军团菌感染的反应中
- 批准号:
10745091 - 财政年份:2023
- 资助金额:
$ 48.24万 - 项目类别:
Role reversal of MAVS in bacterial sepsis
MAVS 在细菌性脓毒症中的作用逆转
- 批准号:
10191010 - 财政年份:2018
- 资助金额:
$ 48.24万 - 项目类别:
相似国自然基金
腺相关病毒载体介导的circ_12952基因治疗通过激活结直肠癌抗肿瘤免疫增强PD-1抗体疗效的机制研究及临床探索
- 批准号:82303073
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
聚合物囊泡靶向骨组织递送mRNA编码抗骨硬化蛋白单链抗体治疗骨质疏松的研究
- 批准号:82372442
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
基于抗原抗体相互作用的抗体定向虚拟设计与筛选
- 批准号:32370697
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
CDK4/6抑制剂通过IFN/JAK/STAT1信号轴增强PD-1抗体抗肝细胞癌疗效的机制研究
- 批准号:82373313
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
P29单克隆抗体的3-羟基丁酰化修饰对其稳定性影响及提升抗泡型包虫病作用的研究
- 批准号:82360402
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
相似海外基金
Development of Targeted Antipseudomonal Bactericidal Prodrugs
靶向抗假单胞菌杀菌前药的开发
- 批准号:
10678074 - 财政年份:2023
- 资助金额:
$ 48.24万 - 项目类别:
Host Directed Orynotide for MDR Gram Negative Bacterial Infections
宿主定向 Orynotide 用于治疗耐多药革兰氏阴性细菌感染
- 批准号:
10674221 - 财政年份:2023
- 资助金额:
$ 48.24万 - 项目类别:
Influence of Early Life Gut Microbiota of HIV-Exposed Uninfected Infants on Inflammation, Growth and Immunity to Enteric Pathogens
暴露于 HIV 的未感染婴儿的早期肠道微生物群对炎症、生长和肠道病原体免疫的影响
- 批准号:
10757205 - 财政年份:2023
- 资助金额:
$ 48.24万 - 项目类别:
Host-pathogen-vector interactions of R. amblyommatis for spotted fever pathogenesis
R. amblyommatis 的宿主-病原体-载体相互作用对斑疹热发病机制的影响
- 批准号:
10610881 - 财政年份:2022
- 资助金额:
$ 48.24万 - 项目类别:
Mechanisms of Dysregulated Innate Immune Responses to Lethal Infections
对致命感染的先天免疫反应失调的机制
- 批准号:
10404732 - 财政年份:2022
- 资助金额:
$ 48.24万 - 项目类别: